The Liver Disease lens in America is under reinvention. What used to be mostly about Hepatitis C and excess alcohol consumption causing, at worst, liver failure, is framed as Fatty Liver Disease aka FLD (Non-Alcoholic and Alcohol-Associated), Hepatitis A through E, and the M word – Metabolic – has arisen.
Non-Alcoholic Fatty Liver Disease aka NAFLD is now called MASLD and MASH*.
Today, there’s a new and better approach to liver ultrasound scanning in the outpatient setting. There are efficacious medications including GLP-1s and Rezdiffra®, with many more FLD meds to come.
And at the pointy peak of hepatology patient escalation are 152 Liver Transplant Centers across the USA.
What’s missing is access.
We’ve launched LiverRight, a National Virtual Clinic for adults at-risk for Liver Disease, and with Liver Disease.
In all 50 US states (plus DC), we diagnose and treat patients via telemedicine, with a one-week guarantee.
The current wait time to see a liver doctor (hepatologist) in America is about 150 days, from our research. LiverRight will get patients in same-week.
We’ll partner with hospital systems large and small, advanced primary care (including ACOs and MCOs), and GI practices. We’ll make early diagnosis a superpower, in no small part because if patients exacerbate to the need for a transplant, there’s no certainty that there will be an available donated liver; they could die while waiting.
We know this: Long Wait Times Prolong Human Suffering. In all forms of Liver Disease, we’ll get patients in within seven (7) calendar days. Our expert providers will diagnose them as needed, and offer longitudinal care, all via video visits. And while honoring the essential in-person components, e.g., imaging and biopsy.
Across all forms of hepatitis and FLD, there are some 70 million American adults with the disease, yet only about 5 million have been diagnosed.
You know what’s next already. Three words.
Book an Appointment.
Contact us about anything (appointments, partnering, jobs, questions, big ideas).
_________
*Metabolic dysfunction-associated steatotic liver disease (MASLD) is a general term for a condition that causes fat to build up in the liver, while metabolic dysfunction-associated steatohepatitis (MASH) is a more severe form of MASLD that involves inflammation of the liver.